Dosing Differences Opined for Costly Hemophilia Option Dosing Differences Opined for Costly Hemophilia Option

Achieving the goal of zero bleeds as patients pursue active lives will require divergent dosing, according to PROPEL trial investigators who evaluated whether more exposure to FVIII improves outcomes.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Related Links:

Publication date: Available online 8 April 2020Source: Journal of Ginseng ResearchAuthor(s): Young Keol Cho, Jung-Eun Kim
Source: Journal of Ginseng Research - Category: Complementary Medicine Source Type: research
RE: Reyes A, Révil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079-2087. Curr Med Res Opin. 2020 Apr 07;:1-3 Authors: Jain N, Lethagen S PMID: 32253943 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Conclusion: Considering the significant economic burden of hemophilia and in order to reduce the costs, the following suggestions can be offered: provision of clotting factor concentrates domestically in accordance with the world standards, and providing specialized services and care to hemophilia patients in towns. PMID: 32249720 [PubMed - in process]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research
by Simon Krooss, Sonja Werwitzke, Johannes Kopp, Alice Rovai, Dirk Varnholt, Amelie S. Wachs, Aurelie Goyenvalle, Annemieke Aarstma-Rus, Michael Ott, Andreas Tiede, J örg Langemeier, Jens Bohne Loss-of-function mutations in the human coagulation factor 9 (F9) gene lead to hemophilia B. Here, we dissected the consequences and the pathomechanism of a non-coding mutation (c.2545A>G) in theF9 3 ’ untranslated region. Using wild type and mutant factor IX (FIX) minigenes we revealed that the mutation leads to reducedF9 mRNA and FIX protein levels and to lower coagulation activity of cell culture supernatants. The ...
Source: PLoS Genetics - Category: Genetics & Stem Cells Authors: Source Type: research
AbstractAtrial fibrillation is the most common cardiac arrhythmia and is a major cause of embolic stroke. In patients at high bleeding risk such as those with hemophilia, the thromboembolic prevention is challenging. We herein present three patients affected by moderate to severe hemophilia and atrial fibrillation that were treated in our Institution between March 2018 and September 2019, with percutaneous left atrial appendage closure. In patients with relative or absolute contraindications to long-term anticoagulant therapy, the left atrial appendage closure could represent a reasonable strategy.
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
INTRODUCTION: Sports participation in children with haemophilia is generally considered to be associated with increased injury risk, which is generally considered highest in severe haemophilia. AIM: To assess sports participation according to age a...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
LOUISVILLE, Ky., April 6, 2020 /PRNewswire/ -- HEMA Biologics, LLC, ( " HEMA Biologics " ) today announced that the U.S. Food and Drug Administration (FDA) approved Sevenfact® [coagulation factor VIIa (recombinant)-jncw] as the first new bypassing...
Source: - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
First new bypassing agent approved for the treatment and control of bleeding episodes in hemophilia A and B patients with inhibitors in over 2 decades Median number of infusions required to achieve bleeding control in the first 12 hours was 1 (225 mcg/k... Biopharmaceuticals, FDA HEMA Biologics, SEVENFACT, coagulation factor VIIa, hemophilia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
THE MANAGEMENT of inherited or acquired coagulation disorders can be challenging during cardiac surgery with extracorporeal circulation. Although guidelines recommend preoperative supplementation of factor XI (FXI) with severe hemophilia C, there are certain risks involved with this strategy with the application of cardiac bypass.
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Tags: Case Report Source Type: research
Abstract Emicizumab is a humanized anti-FIX/FX (factor IXa/X) bispecific monoclonal antibody that mimics FVIIIa (activated factor VIII) cofactor function. The hemostatic efficacy of emicizumab has been confirmed in clinical studies of patients with hemophilia A, irrespective of the presence of FVIII inhibitors. Emicizumab differs in some properties from FVIIIa molecule. Emicizumab requires no activation by thrombin and is not inactivated by activated protein C, but emicizumab-mediated coagulation is regulatable and maintains hemostasis. A small amount of FIXa (activated factor IX) is required to initiate emicizuma...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - Category: Cardiology Authors: Tags: Arterioscler Thromb Vasc Biol Source Type: research
More News: Cancer & Oncology | Haemophilia | Hematology | Hemophilia